Deutsche Bank Starts Teva Pharma (TEVA) at Buy
- DuPont (DD) Tops Q4 EPS by 9c; Sees Merger Closing in First Half
- Barclays Downgrades Apple (AAPL) to Equalweight, Concerned India/China Will not Emerge As Growth Catalysts
- Yahoo! (YHOO) Tops Q4 EPS by 4c; Sees Verizon Deal Closing in Q2, Not Q1
- SAP (SAP) Q4 IFRS Revenues Rises 7%, Boosts 2020 Outlook
- Oppenheimer Downgrades Energous Corp (WATT) to Perform
Deutsche Bank initiated coverage on Teva Pharma (NYSE: TEVA) with a Buy rating and a price target of $63.00.
Analyst Gregg Gilbert said, "While the potential cliff for Copaxone looms and the generics business has not been without challenges, we like the combination of valuation, attractive dividend yield (similar to Big Pharma), and the potential for greater focus on strategic initiatives that increase shareholder value under new CEO Erez Vigodman. We see the recent hire of industry veteran Siggi Olafsson to run global generics and the simplification of the management structure as positive steps, and we sense that investors are skeptical about cost savings initiatives, the entire branded product pipeline, and Teva’s ability/desire to do deals."
Shares of Teva Pharma closed at $54.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Cuts Teva Pharma (TEVA) to Neutral Amid Challenging Generic Environment
- JMP Securities Downgrades Essex Property Trust (ESS) to Market Perform
- Instinet Downgrades DineEquity (DIN) to Neutral
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, New Coverage
Related EntitiesDeutsche Bank, Dividend
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!